Viridian Therapeutics, Inc. VRDN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $141K+6.8% | $132K-99.8% | $70.57M+93,993% | $75K+4.2% | $72K0.0% | ||
| $77.63M-13.0% | $89.21M+3.4% | $86.26M-0.4% | $86.63M+12.7% | $76.84M+6.8% | ||
| $38.68M— | —— | —— | —— | $17.1M+12.0% | ||
| $116.31M-5.3% | $122.88M+11.1% | $110.58M+3.5% | $106.84M+13.7% | $93.94M+7.3% | ||
| -$116.17M+5.4% | -$122.75M-207% | -$40.01M+62.5% | -$106.77M-13.7% | -$93.87M-7.3% | ||
| -82,389.4%+10,602pp | -92,991.7%-92,935pp | -56.7%+142,299pp | -142,356%-11,987pp | -130,369.4%-8,881pp | ||
| $3.46M+5.5% | $3.28M+486% | $560K+8.9% | $514K-6.5% | $550K+6.4% | ||
| $7.87M+1.0% | $7.79M+41.1% | $5.52M-15.7% | $6.55M-13.2% | $7.54M-11.5% | ||
| $11.27M+371% | $2.39M-55.8% | $5.41M-10.2% | $6.03M-13.3% | $6.95M-10.2% | ||
| -$104.9M+12.8% | -$120.36M-248% | -$34.6M+65.7% | -$100.74M-15.9% | -$86.91M-9.0% | ||
| -74,397.9%+16,780pp | -91,178%-91,129pp | -49%+134,264pp | -134,313.3%-13,602pp | -120,711.1%-9,982pp | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | 81.3M— | ||
| —— | —— | —— | —— | —— | ||
| -$105.91M+11.9% | -$120.27M-251% | -$34.31M+66.0% | -$100.91M-16.4% | -$86.66M-7.4% | ||
| $7.53M— | —— | —— | —— | $0— | ||
| -$1.01M-1,300% | $84K-71.4% | $294K+267% | -$176K-169% | $255K+127% | ||
| -$672K+68.2% | -$2.12M-567% | $453K— | $0+100% | -$36K+85.9% | ||
| $77.63M-13.0% | $89.21M+3.4% | $86.26M-0.4% | $86.63M+12.7% | $76.84M+6.8% | ||
| -$116.17M+5.4% | -$122.75M-207% | -$40.01M+62.5% | -$106.77M-13.7% | -$93.87M-7.3% | ||
| -$116.05M+5.4% | -$122.63M-207% | -$39.9M+62.6% | -$106.65M-13.8% | -$93.75M-7.3% | ||
| -$116.05M+5.4% | -$122.63M-207% | -$39.9M+62.6% | -$106.65M-13.8% | -$93.75M-7.3% | ||
| -82,303.5%+10,597pp | -92,900.8%-92,844pp | -56.5%+142,149pp | -142,205.3%-11,998pp | -130,206.9%-8,889pp | ||
| -$116.17M+5.4% | -$122.75M-207% | -$40.01M+62.5% | -$106.77M-13.7% | -$93.87M-7.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Viridian Therapeutics, Inc.'s profit margins?
- Gross margin is 36.3% and operating margin is -543.9%, with a -508.5% net margin.
- Where does Viridian Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.